- Home
- CSPI vs IPHA Comparison
CSPI vs IPHA Comparison
Compare CSPI & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSPI
- IPHA
- Stock Information
- Founded
- CSPI 1968
- IPHA 1999
- Country
- CSPI United States
- IPHA France
- Employees
- CSPI N/A
- IPHA N/A
- Industry
- CSPI EDP Services
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- CSPI Technology
- IPHA Health Care
- Exchange
- CSPI Nasdaq
- IPHA Nasdaq
- Market Cap
- CSPI 146.9M
- IPHA 160.1M
- IPO Year
- CSPI 1987
- IPHA 2019
- Fundamental
- Price
- CSPI $13.70
- IPHA $1.91
- Analyst Decision
- CSPI
- IPHA Strong Buy
- Analyst Count
- CSPI 0
- IPHA 1
- Target Price
- CSPI N/A
- IPHA $11.50
- AVG Volume (30 Days)
- CSPI 28.2K
- IPHA 22.5K
- Earning Date
- CSPI 05-07-2025
- IPHA 03-27-2025
- Dividend Yield
- CSPI 0.81%
- IPHA N/A
- EPS Growth
- CSPI N/A
- IPHA N/A
- EPS
- CSPI 0.02
- IPHA N/A
- Revenue
- CSPI $55,514,000.00
- IPHA $20,831,349.00
- Revenue This Year
- CSPI N/A
- IPHA $220.44
- Revenue Next Year
- CSPI N/A
- IPHA $81.85
- P/E Ratio
- CSPI $793.10
- IPHA N/A
- Revenue Growth
- CSPI N/A
- IPHA N/A
- 52 Week Low
- CSPI $10.76
- IPHA $1.29
- 52 Week High
- CSPI $21.95
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- CSPI 37.32
- IPHA 48.90
- Support Level
- CSPI $14.80
- IPHA $1.76
- Resistance Level
- CSPI $16.55
- IPHA $2.21
- Average True Range (ATR)
- CSPI 0.74
- IPHA 0.12
- MACD
- CSPI -0.13
- IPHA -0.01
- Stochastic Oscillator
- CSPI 7.01
- IPHA 40.00
Stock Price Comparison Chart: CSPI vs IPHA
About CSPI CSP Inc.
CSP Inc along with its subsidiaries develops and markets IT integration solutions, security products, managed IT services, cloud services, purpose-built network adapters, and high-performance cluster computer systems. The firm operates in two segments namely Technology Solutions, where the company focus on value-added reseller integrated solutions including third-party hardware, software, and technical computer-related consulting, and High-Performance Products segments, where the company design, manufacture and deliver products and services to customers that require specialized cyber security services, networking and signal processing. It generates a majority of its revenue from the Technology Solutions segment. Geographically, the company generates its maximum revenue from the Americas.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.